-
Something wrong with this record ?
Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats
L. Uttl, T. Hložek, P. Mareš, T. Páleníček, H. Kubová
Language English Country Switzerland
Document type Journal Article
Grant support
LO1611
Ministry of Education Youth and Sports
RVO: 67985823
Ministry of Health
No. CZ.02.1.01/0.0/0.0/16_025/0007444
Ministry of Education Youth and Sports
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
35008517
DOI
10.3390/ijms23010094
Knihovny.cz E-resources
- MeSH
- Anticonvulsants pharmacology MeSH
- Epilepsy drug therapy MeSH
- Cannabidiol pharmacokinetics pharmacology MeSH
- Rats MeSH
- Disease Models, Animal MeSH
- Brain drug effects MeSH
- N-Methylaspartate pharmacology MeSH
- Pentylenetetrazole pharmacology MeSH
- Rats, Wistar MeSH
- Seizures drug therapy MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1-2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 h after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011653
- 003
- CZ-PrNML
- 005
- 20220506130921.0
- 007
- ta
- 008
- 220425s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms23010094 $2 doi
- 035 __
- $a (PubMed)35008517
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Uttl, Libor $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Topolová 748, 250 67 Klecany, Czech Republic $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic $1 https://orcid.org/0000000305721213
- 245 10
- $a Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats / $c L. Uttl, T. Hložek, P. Mareš, T. Páleníček, H. Kubová
- 520 9_
- $a In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1-2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 h after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antikonvulziva $x farmakologie $7 D000927
- 650 _2
- $a mozek $x účinky léků $7 D001921
- 650 _2
- $a kanabidiol $x farmakokinetika $x farmakologie $7 D002185
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a epilepsie $x farmakoterapie $7 D004827
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a N-methylaspartát $x farmakologie $7 D016202
- 650 _2
- $a pentylentetrazol $x farmakologie $7 D010433
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a záchvaty $x farmakoterapie $7 D012640
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hložek, Tomáš $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic
- 700 1_
- $a Mareš, Pavel $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
- 700 1_
- $a Páleníček, Tomáš $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Topolová 748, 250 67 Klecany, Czech Republic $u Department of Psychiatry and Medical Psychology 3FM CU and NIMH, 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague, Czech Republic
- 700 1_
- $a Kubová, Hana $u Laboratory of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 1 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35008517 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130913 $b ABA008
- 999 __
- $a ok $b bmc $g 1789321 $s 1162851
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 23 $c 1 $e 20211222 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a LO1611 $p Ministry of Education Youth and Sports
- GRA __
- $a RVO: 67985823 $p Ministry of Health
- GRA __
- $a No. CZ.02.1.01/0.0/0.0/16_025/0007444 $p Ministry of Education Youth and Sports
- LZP __
- $a Pubmed-20220425